<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05089942</url>
  </required_header>
  <id_info>
    <org_study_id>ZJSRM2021</org_study_id>
    <nct_id>NCT05089942</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Recombinant Human Insulin Patch ZJSRM2021</brief_title>
  <official_title>Efficacy and Safety of Recombinant Human Insulin Patch ZJSRM2021 in Healthy and Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Provincial People's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the efficacy，safety， and tolerability of the&#xD;
      recombinant human insulin patch ZJSRM2021 in healthy subjects, type 1diabetes mellitus and&#xD;
      type 2diabetes mellitus patients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Recombinant Human Insulin Patch ZJSRM2021</measure>
    <time_frame>maximum 1 years</time_frame>
    <description>the glucose and insulin level after receiving Recombinant Human Insulin Patch ZJSRM2021</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse event of Recombinant Human Insulin Patch ZJSRM2021</measure>
    <time_frame>maximum 1 years</time_frame>
    <description>Any adverse event(such as tachycardia, hypertension, hypoglycemia，coma) of Recombinant Human Insulin Patch ZJSRM2021</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin irritation assessment and pain assessment of Recombinant Human Insulin Patch ZJSRM2021</measure>
    <time_frame>maximum 1 years</time_frame>
    <description>Skin irritation assessment（Score range from 0：no irritation to 7：Intense stimulation such as blisters exceeds the patch coverage) after receiving Recombinant Human Insulin Patch ZJSRM2021</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain assessment of Recombinant Human Insulin Patch ZJSRM2021</measure>
    <time_frame>maximum 1 years</time_frame>
    <description>Pain assessment（Visual Analogue Score，VAS，Score range from 0：no pain to 10：most pain） after receiving Recombinant Human Insulin Patch ZJSRM2021</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>type1diabetes</condition>
  <condition>Type2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Recombinant Human Insulin Patch ZJSRM2021</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>health subjects or diabetic patients receive recombinant human insulin patch ZJSRM2021</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>health subjects receive patch</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Human Insulin Patch ZJSRM2021</intervention_name>
    <description>health subjects receive recombinant human insulin patch ZJSRM2021，diabetic patients receive recombinant human insulin patch ZJSRM2021（low-dosage or high dosage）</description>
    <arm_group_label>Recombinant Human Insulin Patch ZJSRM2021</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>health subjects receive placebo patch</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 1or type 2 diabetes Body mass index：19~35kg/m2（include） HbA1c≤11.0% Diabetic&#xD;
             duration of T1DM was ≥1 year, and the subjects received insulin injections during the&#xD;
             past year .Metformin and glycosidase inhibitors were also allowed.&#xD;
&#xD;
        Newly diagnosed T2DM or metformin-only, and the drug dose remained stable for ≥30 days. Or&#xD;
        T2DM patients withdrawed drug ≥30 days of drug after diagnosis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  other type diabetes Use of other oral antidiabetics drugs within the 1 months prior to&#xD;
             screening. With a history of malignant tumor. With acute or chronic infection. With&#xD;
             evidence of major active psychiatric disorders. Drug abuse or alcohol abuse. Drunk too&#xD;
             much tea or coffee(more than 2000ml per day). History of any drug allergies.&#xD;
             Anti-insulin antibody positive. Participated in clinical trials within 3 months prior&#xD;
             to signing the informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaohong X Wu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Endocriology, Zhejiang Provincial People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiao Ye</last_name>
    <phone>+8657185893937</phone>
    <email>semper_fi@foxmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yu Lei</last_name>
    <phone>+8657185893937</phone>
    <email>semper_fi@foxmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhejiang provincial people's hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 20, 2021</study_first_submitted>
  <study_first_submitted_qc>October 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang Provincial People's Hospital</investigator_affiliation>
    <investigator_full_name>Xiao Ye, MD</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>insulin patch</keyword>
  <keyword>type 1 diabetes mellitus</keyword>
  <keyword>type 2 diabetes mellitus</keyword>
  <keyword>safety</keyword>
  <keyword>efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to share data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

